Cytokine Release Syndrome
Vaccine to prevent pancreatic, colorectal cancer relapse yields ‘exciting’ early results
Results of a phase 1 trial for a vaccine targeting micrometastatic disease markers in patients already treated for pancreatic or colorectal cancer showed potential in preventing recurrence, according to a study in Nature Medicine.
FDA official says CAR-T ‘incredibly beneficial’ despite secondary malignancy risk
Benefits of chimeric antigen receptor T-cell therapy far outweigh the risks involved, including secondary T-cell malignancies, according to Peter Marks, MD, PhD, director of the FDA’s Center for Biologic Evaluation and Research.
Infections cause ‘high’ rate of nonrelapse deaths among CAR-T recipients
SAN DIEGO — Infections are the main driver of mortality not related to disease relapse among individuals who received chimeric antigen receptor T cells, results of a meta-analysis presented at ASH Annual Meeting and Exhibition showed.
‘Exciting’ results show anito-cel CAR-T is safe, durable for high-risk multiple myeloma
SAN DIEGO — All 38 patients with heavily pretreated multiple myeloma responded to an investigational chimeric antigen receptor T-cell therapy, results of a phase 1 study presented at ASH Annual Meeting and Exhibition showed.
Aggressive management may lead to fewer cardiac events after CAR T-cell therapy
Adults undergoing chimeric antigen receptor T-cell therapy are at low risk for major adverse cardiovascular events, according to data published in JACC: CardioOncology.
Epcoritamab induces response in relapsed/refractory follicular lymphoma
More than 80% of a cohort of adults with relapsed or refractory follicular lymphoma exhibited an overall response to subcutaneously administered epcoritamab-bysp, according to topline data from the agent’s manufacturer.
Bellicum Pharmaceuticals ends CAR-T trials for solid tumors after risk-benefit review
Bellicum Pharmaceuticals discontinued clinical trials for two investigational chimeric antigen receptor T-cell therapies, the company announced today.
CAR T-cell therapy, new drugs ushering in ‘lupus renaissance’
SCOTTSDALE, Ariz. — Several new drugs and promising therapies, including chimeric antigen receptor T-cell therapy, have ushered in a “lupus renaissance,” said a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.
FDA grants accelerated approval to Lunsumio for relapsed, refractory follicular lymphoma
The FDA granted accelerated approval to mosunetuzumab-axgb for treatment of adults with relapsed or refractory follicular lymphoma, the agency announced in a press release.
Novel CAR-T effective for most patients with advanced multiple myeloma
A chimeric antigen receptor T-cell therapy produced a response rate of 71% among patients with relapsed or refractory multiple myeloma, according to phase 1 study results published in The New England Journal of Medicine.